SEC Tracker
Get the app

Arcutis Biotherapeutics ARQT

Matsuda Masaru (officer) plans to sell 12,058 ARQT shares, about $313,878

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Mar 2, 2026
  2. Broker: Merrill Lynch
  3. Shares acquired by: Restricted Stock Vesting
  4. 10b5-1 plan adopted: Jun 6, 2025

All of Matsuda Masaru's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 3,325 shares at $27.95 on Feb 27, 2026 · Form 4
  • Sold 6,553 shares at $25.16 on Mar 2, 2026 · Form 4
  • Sold 1,987 shares at $25.7 on Mar 2, 2026 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Arcutis Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  2. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  3. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  4. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.